Nexalin Technology, Inc. (NXL) AI Stock Analysis
NXL AI stock analysis summary
AI ResearchNexalin Technology, Inc. (NXL) is a clinical-stage medical device company focused on non-invasive neurostimulation therapies for mental health and neurological conditions. For the trailing twelve months, the company generated $217,155 in revenue while recording an operating margin of -18479.7% and an EPS of -$14.10. Over the past year, NXL shares fell 94.1%, closing at $2.35 as of October 16, 2026.
- Market cap
- $2.5M
- Revenue (TTM)
- $217,155
- P/E
- —
- 1Y return
- -94.1% S&P 500 16.8%
- Avg. target
- $15.00 538.3% vs last close
Bull case
- Gross margins have stayed consistently elevated, reaching 79.7% in FY2025.
- Analyst consensus sets a mean price target of $15.00, which is 538.3% above the last close.
- For the next fiscal year, analysts project revenue to expand by 76.0% to $338,000.
Bear case
- The company burned -$5.0M in operating cash flow in FY2025 against a cash balance of just $1.0M as of June 30, 2026.
- Shareholder dilution has been substantial, with share count increasing by 351.8% over five years.
- The stock has dropped 94.1% over the past 12 months and trades 80.1% below its 200-day average.
What Nexalin Technology does
Nexalin Technology, Inc. is a medical device company dedicated to advancing neurostimulation products tailored for mental health treatment in both the United States and China. Central to its offerings is the Nexalin Device, a non-invasive and drug-free therapy designed specifically for alleviating anxiety and insomnia. The device emits a patented frequency-based waveform that targets mid-brain structures associated with various mental health disorders. Headquartered in Houston, Texas, and founded in 2021, the company is actively involved in the ongoing clinical development of Generation 2. Generation 2 aims to expand treatment capabilities to address substance abuse related to opiates, chronic pain, Alzheimer's disease, and dementia.
Growth and profitability
Nexalin Technology grew annual revenue from $144,065 in FY2021 to $301,647 in FY2025, recording a 5-year revenue CAGR of 4.4%. Revenue experienced significant volatility, jumping 817.2% to $1.3M in FY2022 before dropping 91.6% to $110,748 in FY2023. Gross margin remained steady, coming in at 79.7% in FY2025 with an operating margin of -2781.7%. Net loss widened from -$6.1M in FY2021 to -$8.2M in FY2025, with EPS finishing at -$0.51. In the latest quarter ended June 30, 2026, quarterly revenue fell 82.8% year-over-year, while trailing twelve month revenue stood at $217,155.
Balance sheet and cash flow
As of June 30, 2026, Nexalin Technology held $1.0M in cash and short-term investments, with total assets of $3.0M and shareholders' equity of $1.5M. The current ratio stood at 1.25. The company has sustained ongoing operational cash burn, reporting an operating cash flow of -$5.0M and free cash flow of -$5.0M in FY2025. Capital expenditures for FY2025 totaled $96,859. Over the past five years, the company's share count increased by 351.8%.
Valuation and performance
At a last close of $2.35 on October 16, 2026, Nexalin Technology had a market capitalization of $2.5M and an enterprise value of $3.0M. The stock trades at a price-to-sales multiple of 11.3x and an EV-to-revenue multiple of 13.8x, compared to the median of 4.1x price-to-sales for its US-listed Healthcare peers. Its price-to-book ratio is 2.6x. Over the past year, NXL shares declined 94.1%, while the S&P 500 (SPY) gained 16.8%.
What analysts expect
Wall Street coverage includes 1 Buy rating, 0 Strong Buy, 0 Hold, 0 Sell, and 0 Strong Sell ratings. The mean price target is $15.00, representing a 538.3% premium over the last close of $2.35. For the fiscal year ending December 31, 2026, consensus estimates anticipate revenue of $192,000 and an EPS of -$11.42. For the following fiscal year, 1 analyst projects revenue of $338,000 and an EPS of -$7.55. Nexalin beat EPS estimates in 1 of the last 4 quarters, with its next earnings date scheduled for November 13, 2026.
Key risks and what to watch
- Revenue in the latest quarter ending June 30, 2026, declined 82.8% year-over-year to bring TTM revenue to $217,155.
- Operating margin for the trailing twelve months stands at -18479.7%, driven by continuing clinical development and overhead costs.
- The stock exhibits high market sensitivity with a beta of 4.11.
- Liquid resources remain constrained with a current ratio of 1.25 and $1.0M in cash and short-term investments.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this NXL AI stock analysis
This page is an AI-written research summary of Nexalin Technology, Inc. (NXL). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: NXL income statement, NXL balance sheet, NXL key metrics, NXL analyst forecast, NXL chart. See the NXL stock overview for the latest quote and news.
NXL AI stock analysis FAQ
What does Nexalin Technology do?
Nexalin Technology, Inc. is a medical device firm that develops non-invasive neurostimulation treatments for mental health conditions, including anxiety and insomnia, and is developing its Generation 2 device for conditions like substance abuse, chronic pain, and Alzheimer's disease.
Does Nexalin Technology pay a dividend?
No, Nexalin Technology does not pay a dividend.
What is the analyst price target for NXL stock?
The 1 analyst covering the stock has a mean price target of $15.00, which is 538.3% above its last closing price of $2.35.
When does Nexalin Technology report earnings next?
The company is scheduled to report its next financial results on November 13, 2026.